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We have identified a novel fusion gene NDEL1-PDGFRB in an 18-month old child 24 
with a myeloid neoplasm and eosinophilia1, 2. In contrast to earlier data on fusion 25 
genes involving PDGRFB in myeloid malignancies, which were generally responsive 26 
to treatment with imatinib3, the patient presented became refractory to both imatinib 27 
and nilotinib. Sequencing of a pertinent gene panel including NRAS, KRAS, NF1, 28 
PTPN11, CBL, FLT3, c-KIT, PDGFRA, CSF1R, CSF3R, SF3B1, SRSF2, ZRSR2, 29 
SH2B3, RUNX1, EZH2, ASXL1, SETBP1, DNMT3A, TET2, PTEN at the time of 30 
diagnosis and both relapses revealed no mutations. However, sequence analysis of 31 
the entire tyrosine kinase domain (TKD) of PDGFRB revealed the D850E mutation in 32 
the activation loop (A-loop). This mutation was identified in peripheral blood (PB) and 33 
bone marrow (BM) specimens from both relapses in virtually all cells belonging to the 34 
leukemic clone, but was undetectable in the diagnostic PB or BM. In order to 35 
elucidate the structural effects mediated by the D850E mutation in the PDGFRβ TKD, 36 
we have generated structure models of the kinase domain both in active (DFG-in) 37 
and inactive (DFG-out) conformations, which interact preferentially with type-I and 38 
type-II TKIs, respectively (Fig.1)4. Since the structure of PDGFRβ TKD at the level of 39 
atomic resolution is not yet available, we have modelled the kinase domain on the 40 
basis of crystallographic structures of closely related homologous proteins including 41 
c-KIT, CSF-1R and VEGFR2. All structural models indicated that the observed type-II 42 
TKI resistance of cells expressing the D850E mutation in NDEL1-PDGFRβ was 43 
conceivably related to stabilization of the A-loop in the active conformation. In this 44 
conformation, the DFG triad serving as a hypomochlion for the A-loop, adopts the so-45 
called DFG-in position5. The modelled structure of the inactive DFG-out conformation 46 
(Fig.1A;orange) revealed the typical auto-inhibitory interaction between D850 and the 47 
amino acid at the +3 position, R853, which is commonly observed in inactive TKDs of 48 
other receptor tyrosine kinases (RTKs) from the PDGFR family, and is believed to 49 
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stabilize the A-loop in the inactive conformation (Fig.1B)6-8. However, modelling of 50 
the mutant PDGFRβ TKD in the inactive conformation could not explain the 51 
resistance to type-II TKIs and the enhanced kinase activity addressed below, 52 
because the negatively charged E850 is also able to form a salt bridge with the 53 
positively charged side chain of R853. By contrast, the DFG-in model suggested the 54 
occurrence of two intriguing amino acid interactions upon transition of the A-loop from 55 
inactive to the active state (Fig.1A;green). One interaction implicated the negatively 56 
charged D850 and the positively charged, conserved H657 in the αC-helix (Fig.1C), 57 
which is expected to stabilize the A-loop in the active conformation9. This interaction 58 
can be further enhanced by the D850E mutation, because the longer side chain of 59 
glutamate in comparison to aspartate brings the negatively charged carboxylic group 60 
1.1 Å closer to the positively charged histidine. This increases the stability of the A-61 
loop in the active conformation (Fig.1D), because the forces of electrostatic 62 
interaction between opposite charges increase with the second power of decreasing 63 
distance, and become largely ineffective at distances exceeding 4.5 Å10. The 64 
structural model also suggested that the mutation H657K would have an effect similar 65 
to the mutation D850E in terms of stabilizing the active conformation (Fig.1E). The 66 
other interaction involved R853 and E946 in the C-lobe of the TKD. The +3 position 67 
to D850 is one of the least conserved positions in the A-loop of RTKs from the 68 
PDGFR family (Fig.1H), and the arginine at this position in PDGFRβ (R853) has the 69 
longest side chain among all members. The DFG-in model suggested that the 70 
positively charged side chain of R853 can reach a distance of approximately 2.7 Å to 71 
the negatively charged carboxyl group of E946, which may facilitate electrostatic 72 
bonds and provide additional stabilization of the DFG-in conformation of the PDGFRβ 73 
TKD. The structural model therefore suggested resistance of NDEL1-PDGFRB with 74 
the D850E mutation to type-II TKIs, which can only bind to the inactive conformation 75 
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of the PDGFRβ TKD, but indicated sensitivity to type-I TKIs binding to the active 76 
conformation. To address the predictions provided by the protein model, we have 77 
introduced several mutations affecting the aforementioned interactions, and tested 78 
the sensitivity of generated constructs against a panel of TKIs. 79 
To assess the oncogenic potential of the newly identified fusion gene, the murine cell 80 
line Ba/F3 was stably transduced with wildtype or mutant NDEL1-PDGFRB 81 
constructs by employing a transposon-based system11. In addition to the D850E 82 
mutation observed in the patient, a construct carrying the H657K mutation was 83 
generated. This mutation was expected to strengthen the electrostatic interaction 84 
between D850 and the αC-helix, thus stabilizing the DFG-in conformation of the 85 
PDGFRβ TKD (Fig.1E).  In order to determine the influence of R853 in the PDGRFβ 86 
TKD on the kinase activity and TKI-sensitivity, constructs carrying R853H were 87 
generated (Fig.1G). Ba/F3 cells expressing the H657K and D850E mutant versions of 88 
NDEL1-PDGFRB displayed an elevated in vitro kinase activity, whereas constructs 89 
with the R853H mutation showed a kinase activity identical to cells carrying wildtype 90 
NDEL1-PDGFRB. The phosphorylation level of PDGFRβ and one of its downstream 91 
targets, Erk, which is activated via the Ras-pathway12, was higher in Ba/F3-NDEL1-92 
PDGFRB cells carrying the H657K or D850E mutations in comparison to wildtype or 93 
R853H-carrying fusion gene constructs (Fig.2B).  94 
The in vitro responsiveness of Ba/F3-NDEL1-PDGFRB cells to different TKIs of type-I 95 
(dasatinib, midostaurin, pacritinib) and type-II (imatinib, nilotinib, sorafenib) was 96 
determined by MTT assays. Cells expressing wildtype NDEL1-PDGFRB were 97 
sensitive to all TKIs tested (Fig.2A). By contrast, proliferation of Ba/F3 cells carrying 98 
the D850E mutation in the NDEL1-PDGFRB gene could only be inhibited by the 99 
indicated type-I TKIs at sub-micromolar concentrations (Fig.2A). The observation of 100 
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TKI resistance apparently induced by the D850E mutation in the kinase domain of 101 
PDGFRβ was in contrast to the same amino acid exchange at the corresponding site 102 
in PDGFRα (D842E)13. This finding raised questions regarding important structural 103 
differences between the two highly homologous RTKs. While PDGFRβ displays an 104 
arginine in the +3 position to the mutation site (R853), PDGFRα has the much shorter 105 
and less basic histidine in the corresponding position (H845) (Fig.1H). It appeared 106 
conceivable therefore that interaction between the side chains of R853 and E946 in 107 
the mutant PDGFRβ TKD could stabilize the active conformation in the presence of 108 
H657K or D850E mutations, thus mediating resistance to type-II TKIs. To address 109 
this notion, the mutation R853H was introduced into NDEL1-PDGFRB constructs, 110 
thus mimicking the sequence of the A-loop in the PDGFRα TKD (Fig.1H). In line with 111 
the properties of the D842E mutation in the FIP1L1-PDGFRα fusion, this change 112 
restored the TKI type-II sensitivity of cells carrying one of the activating mutations, 113 
H657K or D850E, in NDEL1-PDGFRβ (Fig.2). 114 
The position of the newly identified mutation D850E in PDGFRβ corresponds to well-115 
known mutation sites within the activation loop of other members of the PDGFR-RTK 116 
family including c-KIT (D816)14, PDGFRα (D842)13, 15, and FLT3 (D835)5 (Fig.1H). 117 
Mutations converting the aspartate residue at the indicated positions into a bulky 118 
hydrophobic residue were shown to mediate resistance to type-II TKIs5, 15, 16. 119 
Structural studies revealed that the interaction of the residues D816 in c-KIT and 120 
D835 in FLT3 with the residue at the +3 position (N819 in c-KIT and S838 in FLT3) 121 
may maintain the auto-inhibitory inactive conformation of the A-loop6. Notably, 122 
clinically relevant activating mutations D816V in c-KIT and D835V/Y in FLT3 123 
converting the aspartate into a residue with bulky hydrophobic or aromatic side chain 124 
would disrupt the hydrophilic interactions with the corresponding residue at +3 125 
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position. However, a conversion of aspartate to glutamate, representing an exchange 126 
between two hydrophilic and negatively charged amino acids at this position, has 127 
never been associated with resistance to type-II TKIs5, 13, 16. In marked contrast to the 128 
clinical and in vitro data presented, the identical mutation at the corresponding site in 129 
the tyrosine kinase domain of PDGFRα (D842E) in the fusion gene FIP1L1-PDGFRA 130 
associated with chronic eosinophilic leukemia did not cause any significant increase 131 
in IC50 values of the type-II TKIs imatinib, nilotinib, and sorafenib13 (Fig.2A). Similarly, 132 
the same mutation at the corresponding site of FLT3 associated with acute myeloid 133 
leukemia, D835E, did not significantly increase the IC50 to the type-II TKIs sunitinib 134 
and sorafenib5, 16 but enhanced the kinase activity of FLT3, and mediated growth 135 
factor-independent proliferation of the murine hematopoietic cell line Ba/F317. 136 
However, although these analogies are in line with the enhanced kinase activity of 137 
the D850E PDGFRβ mutant, they do not explain the observed resistance to type-II 138 
TKIs. In this regard, it is important to examine the protein model in the context of 139 
intramolecular interactions specific for PDGFRβ TKD. Protein modelling of the 140 
PDGFRβ TKD suggested that the residue in +3 position, R853, which differs from 141 
corresponding sites in all other RTKs of the PDGFR family, mediates a critical amino 142 
acid interaction stabilizing the A-loop in the active conformation, thereby preventing 143 
the interaction of type-II TKIs with their target sites in the kinase domain. This notion 144 
was confirmed by mutating R853 to histidine, the amino acid present at the 145 
corresponding site in PDGFRα, which decreased the kinase activity and restored 146 
sensitivity of NDEL1-PDGFRβ with D850E or H657K to type-II TKIs. The findings not 147 
only confirm the important role of R853 in establishing the resistant phenotype of the 148 
mutant NDEL1-PDGFRB, but also underline the potential of protein modelling for 149 
prediction of sensitivity and resistance to TKI treatment. The data presented provide 150 
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new insights into specific amino acid interactions in mutant RTKs which are of clinical 151 
relevance for improved selection of appropriate TKI treatment.  152 
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Figure Legends 230 
Figure 1. Protein models of the PDGFRβ TKD structure 231 
(A) The modelled DFG-out (orange) and DFG-in (green) conformations of PDGFRβ TKD are 232 
displayed. The zoom-in windows show the relevant stabilizing electrostatic interactions with the 233 
corresponding distances between charges: (B) D850-R853 in the DFG-out model; (C) H657-D850, (D) 234 
H657-E850, (E) K657-D850, (F) R853-E946, and (G) H853-E946 in the DFG-in model. Oxygen atoms 235 
carrying negative charge are marked in red, nitrogen atoms carrying positive charge in blue. The grey 236 
arrow in the center indicates rotation of the A-loop upon transition from inactive to active state. (H) 237 
Sequence alignment of RTKs from the PDGFR family depicting the region covering αC-helices and A-238 
loops of PDGFRα, PDGFRβ, FLT3, CSF-1R, and c-Kit. 239 
Figure 2. TKI-responsiveness of wildtype and mutant NDEL1-PDGFRB genes 240 
(A) Displayed are IC50 values of different TKIs against Ba/F3 cells expressing wildtype (wt) or mutant 241 
NDEL1-PDGFRβ fusion proteins. The corresponding IC50 values for Ba/F3 expressing FIP1L1-242 
PDGFRα WT and D842E are given for comparison. (B) Western blot analysis of Ba/F3 cells 243 
transduced with wildtype or mutant (R = R853H, H = H657K, HR = H657K/R853H, D = D850E, and 244 
DR = D850E/R853H) NDEL1-PDGFRB genes. The phosphorylation levels of NDEL1-PDGFRβ at 245 
Y751 and Y857, and Erk are displayed. Shown are also the total expression levels of NDEL1-246 
PDGFRβ, Erk, and the control gene Gapdh upon mock treatment for 4 h with DMSO (indicated by “-“) 247 
or with 100 nM nilotinib (indicated by “+”). 248 


